Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

393 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Opposing Roles of SPOP Mutations in Human Prostate and Endometrial Cancers.
Cavalcante L, Deshmukh SK, Ribeiro JR, Carneiro BA, Dizon DS, Angara K, Mattox T, Wu S, Xiu J, Walker P, Oberley M, Nabhan C, Huang H, Antonarakis ES. Cavalcante L, et al. Among authors: antonarakis es. JCO Precis Oncol. 2023 Sep;7:e2300088. doi: 10.1200/PO.23.00088. JCO Precis Oncol. 2023. PMID: 37677121
Differential Activity of PARP Inhibitors in BRCA1- Versus BRCA2-Altered Metastatic Castration-Resistant Prostate Cancer.
Taza F, Holler AE, Fu W, Wang H, Adra N, Albany C, Ashkar R, Cheng HH, Sokolova AO, Agarwal N, Kessel A, Bryce A, Nafissi N, Barata P, Sartor AO, Bastos D, Smaletz O, Berchuck JE, Taplin ME, Aggarwal R, Sternberg CN, Vlachostergios PJ, Alva AS, Su C, Marshall CH, Antonarakis ES. Taza F, et al. Among authors: antonarakis es. JCO Precis Oncol. 2021 Jul 22;5:PO.21.00070. doi: 10.1200/PO.21.00070. eCollection 2021. JCO Precis Oncol. 2021. PMID: 34778690 Free PMC article.
Genomic Biomarkers and Genome-Wide Loss-of-Heterozygosity Scores in Metastatic Prostate Cancer Following Progression on Androgen-Targeting Therapies.
Zurita AJ, Graf RP, Villacampa G, Raskina K, Sokol E, Jin D, Antonarakis ES, Li G, Huang RSP, Casanova-Salas I, Vivancos A, Carles J, Ross JS, Schrock AB, Oxnard GR, Mateo J. Zurita AJ, et al. Among authors: antonarakis es. JCO Precis Oncol. 2022 Jul;6:e2200195. doi: 10.1200/PO.22.00195. JCO Precis Oncol. 2022. PMID: 35820087 Free PMC article.
SPOP Mutations as a Predictive Biomarker for Androgen Receptor Axis-Targeted Therapy in De Novo Metastatic Castration-Sensitive Prostate Cancer.
Swami U, Graf RP, Nussenzveig RH, Fisher V, Tukachinsky H, Schrock AB, Li G, Ross JS, Sayegh N, Tripathi N, Mathew Thomas V, Oxnard GR, Antonarakis ES, Agarwal N. Swami U, et al. Among authors: antonarakis es. Clin Cancer Res. 2022 Nov 14;28(22):4917-4925. doi: 10.1158/1078-0432.CCR-22-2228. Clin Cancer Res. 2022. PMID: 36088616
Metastatic Prostate Cancers with BRCA2 versus ATM Mutations Exhibit Divergent Molecular Features and Clinical Outcomes.
Hwang J, Shi X, Elliott A, Arnoff TE, McGrath J, Xiu J, Walker P, Bergom HE, Day A, Ahmed S, Tape S, Makovec A, Ali A, Shaker RM, Toye E, Passow R, Lozada JR, Wang J, Lou E, Mouw KW, Carneiro BA, Heath EI, McKay RR, Korn WM, Nabhan C, Ryan CJ, Antonarakis ES. Hwang J, et al. Among authors: antonarakis es. Clin Cancer Res. 2023 Jul 14;29(14):2702-2713. doi: 10.1158/1078-0432.CCR-22-3394. Clin Cancer Res. 2023. PMID: 37126020
MLH1 Loss in Primary Prostate Cancer.
Nourmohammadi Abadchi S, Sena LA, Antonarakis ES, Pritchard CC, Eshleman JR, Konnick EQ, Salipante SJ, Shenderov E, Lotan TL. Nourmohammadi Abadchi S, et al. Among authors: antonarakis es. JCO Precis Oncol. 2023 May;7:e2200611. doi: 10.1200/PO.22.00611. JCO Precis Oncol. 2023. PMID: 37196219
Pan-Cancer Analysis of Copy-Number Features Identifies Recurrent Signatures and a Homologous Recombination Deficiency Biomarker to Predict Poly (ADP-Ribose) Polymerase Inhibitor Response.
Moore JA, Chen KT, Madison R, Newberg JY, Fleischmann Z, Wang S, Sharaf R, Murugesan K, Fendler BJ, Hughes J, Schrock AB, Hegde PS, Oxnard GR, Fabrizio D, Frampton GM, Antonarakis ES, Sokol ES, Jin DX. Moore JA, et al. Among authors: antonarakis es. JCO Precis Oncol. 2023 Sep;7:e2300093. doi: 10.1200/PO.23.00093. JCO Precis Oncol. 2023. PMID: 37769224
Co-occurring BRCA2/SPOP Mutations Predict Exceptional Poly (ADP-ribose) Polymerase Inhibitor Sensitivity in Metastatic Castration-Resistant Prostate Cancer.
Orme JJ, Taza F, De Sarkar N, Tewari AK, Arsalan Naqvi S, Riaz IB, Childs DS, Omar N, Adra N, Ashkar R, Cheng HH, Schweizer MT, Sokolova AO, Agarwal N, Barata P, Sartor O, Bastos D, Smaletz O, Berchuck JE, McClure H, Taplin ME, Aggarwal R, Sternberg CN, Vlachostergios PJ, Alva AS, Mehra N, Nelson PS, Hwang J, Dehm SM, Shi Q, Fleischmann Z, Sokol ES, Elliott A, Huang H, Bryce A, Marshall CH, Antonarakis ES. Orme JJ, et al. Among authors: antonarakis es. Eur Urol Oncol. 2023 Dec 9:S2588-9311(23)00277-8. doi: 10.1016/j.euo.2023.11.014. Online ahead of print. Eur Urol Oncol. 2023. PMID: 38072760
Natural Killer Cell Infiltration in Prostate Cancers Predict Improved Patient Outcomes.
Zorko NA, Makovec A, Elliott A, Kellen S, Lozada JR, Arafa AT, Felices M, Shackelford M, Barata P, Zakharia Y, Narayan V, Stein MN, Zarrabi KK, Patniak A, Bilen MA, Radovich M, Sledge G, El-Deiry WS, Heath EI, Hoon DSB, Nabhan C, Miller JS, Hwang JH, Antonarakis ES. Zorko NA, et al. Among authors: antonarakis es. Prostate Cancer Prostatic Dis. 2024 Feb 28. doi: 10.1038/s41391-024-00797-0. Online ahead of print. Prostate Cancer Prostatic Dis. 2024. PMID: 38418892
393 results